Navigating the Biopharma Depression: More Pain or 2023 Gain? – October 20th, 2022
Navigating the Biopharma Depression: More Pain or 2023 Gain? – October 20th, 2022 Click Here for a full summary of […]
Navigating the Biopharma Depression: More Pain or 2023 Gain? – October 20th, 2022 Click Here for a full summary of […]
The State of Biopharma: Navigating a Stormy Climate – July 26th, 2022 Click Here for a full summary of the
Biotech Is Down But Not Out: Developing A Game Plan In A Volatile Market – April 27th, 2022 Click Here for
Locust Walk Stem Cell Tx Conference in partnership with Harvard Stem Cell Institute April 11th, 2022, Conference in Review We
On this episode of Biotalk, Locust Walk’s Geoff Meyerson welcomes Stephen Sands, former Vice Chairman of Investment Banking and Chairman of the Global
Life sciences firm Locust Walk’s plans for its $175M SPAC Geoff Meyerson co-founded Locust Walk, a Boston-based life sciences consulting
Biopharma’s COVID Capital Comeback What a difference a few months can make – especially during a pandemic. Heading into 2020,
Transaction Case Studies MULTI-TRACK ENGAGEMENT LEADING TO AN EQUITY INVESTMENT Situation Assessment Rapid Micro Biosystems is a privately held, commercial
Transaction Case Studies GLOBAL DEAL WITH A JAPANESE COMPANY FOR BRINCIDOFOVIR, A BROAD-SPECTRUM ANTIVIRAL FOR THE TREATMENT AND PREVENTION OF
Transaction Case Studies RAPID M&A ADVISORY Situation Assessment Anokion Bio is Swiss biotechnology company focused on autoimmune diseases by restoring